Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Trial details
- Registry ID
- NCT04735536
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Study Drug; Study Drug Active; zervimesine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536 | Cognition Therapeutics | Phase 2 | Completed | 2023-04-26Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790 | Cognition Therapeutics | Phase 2 | Completed | 2024-05-29Actual |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415 | Cognition Therapeutics | Phase 2 | Completed | 2024-11-25Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 | Cognition Therapeutics | Phase 2 | Active not recruiting | 2027-05-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |